Holding(s) in Company

e-Therapeutics plc
05 February 2008



                               e-Therapeutics plc

                                (the 'Company')



       Notification of Change of Interest in the Company's Share Capital





On 4 February 2008, the Company received notification that, following disposals
of a total of 200,000 ordinary shares of 0.1p each in the capital of the Company
('Ordinary Shares') between 28 January 2008 and 31 January 2008 (the individual
disposals were: 100,000 Ordinary Shares on 28 January, 25,000 Ordinary Shares on
both 29 and 30 January and 50,000 Ordinary Shares on 31 January), RAB Special
Situations (Master) Fund Limited ('RAB') is the beneficial owner of 17,207,950
Ordinary Shares, representing 30.89 per cent. of the total number of Ordinary
Shares and of the total voting rights of the Company.  The registered holder of
these Ordinary Shares is Credit Suisse Client Nominees (UK) Limited.



RAB has only disposed of a very small proportion of its Ordinary Shares and
remains a strong supporter of the Company going forward.



For more information please contact:
John Cordiner, e-Therapeutics plc                      Tel: [phone]


Richard Lindley, WH Ireland Limited                    Tel: [phone]






                      This information is provided by RNS
            The company news service from the London Stock Exchange